Eli Lilly and Company (VIE:LLYC)

Market Cap	790.23B
Revenue (ttm)	50.64B
Net Income (ttm)	15.69B
Shares Out	n/a
EPS (ttm)	17.42
PE Ratio	50.36
Forward PE	33.97
Dividend	5.56 (0.64%)
Ex-Dividend Date	Nov 14, 2025

Volume	133
Average Volume	79
Open	867.60
Previous Close	865.70
Day's Range	865.60 - 884.10
52-Week Range	539.10 - 887.00
Beta	n/a
RSI	78.01
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: LLYC

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD